PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer
出版年份 2019 全文链接
标题
PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer
作者
关键词
-
出版物
Scientific Reports
Volume 9, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-01-24
DOI
10.1038/s41598-018-36096-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
- (2018) Chunyan Yue et al. OncoImmunology
- Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study
- (2018) Yan-bin Chen et al. TUMORI
- Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
- (2017) Alexander Le et al. Therapeutics and Clinical Risk Management
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The incorporation of microfluidics into circulating tumor cell isolation for clinical applications
- (2016) Molly Kozminsky et al. Current Opinion in Chemical Engineering
- Current clinical trials testing the combination of immunotherapy with radiotherapy
- (2016) Josephine Kang et al. Journal for ImmunoTherapy of Cancer
- Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
- (2016) Chiara Nicolazzo et al. Scientific Reports
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
- (2015) Xiangjiao Meng et al. CANCER TREATMENT REVIEWS
- Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer
- (2015) V. K. Anagnostou et al. CLINICAL CANCER RESEARCH
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
- (2015) Wendy A. Cooper et al. LUNG CANCER
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Frequent expression of PD-L1 on circulating breast cancer cells
- (2015) Martine Mazel et al. Molecular Oncology
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
- (2014) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment
- (2014) Laura Muinelo-Romay et al. Cancers
- Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) J. Vansteenkiste et al. ANNALS OF ONCOLOGY
- Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine
- (2013) O. Juan et al. Clinical & Translational Oncology
- Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung cancer cells enabled by the VerIFAST platform
- (2013) Benjamin P. Casavant et al. LAB ON A CHIP
- Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets
- (2013) Hyeun Joong Yoon et al. Nature Nanotechnology
- Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
- (2012) E. A. Punnoose et al. CLINICAL CANCER RESEARCH
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer
- (2011) Matthew G. Krebs et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of Mutations inEGFRin Circulating Lung-Cancer Cells
- (2008) Shyamala Maheswaran et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More